Japan Tissue Engineering First Quarter 2025 Earnings: JP¥5.20 loss per share (vs JP¥0.32 profit in 1Q 2024)

Japan Tissue Engineering (TSE:7774) First Quarter 2025 Results

Key Financial Results

• Revenue: JP¥442.0m (down 33% from 1Q 2024).
• Net loss: JP¥211.0m (down from JP¥13.0m profit in 1Q 2024).
• JP¥5.20 loss per share (down from JP¥0.32 profit in 1Q 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Japan Tissue Engineering Earnings Insights

Looking ahead, revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Japan.

Performance of the Japanese Biotechs industry.

The company's shares are down 11% from a week ago.

Risk Analysis

We should say that we've discovered 1 warning sign for Japan Tissue Engineering that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com